topiramate off-label weight
Selected indexed studies
- Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations. (Adv Ther, 2023) [PMID:37368102]
- Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. (JAMA, 2014) [PMID:24825644]
- Topiramate: antipsychotic-induced weight gain. (Hosp Pharm, 2014) [PMID:24958940]
_Worker-drafted node — pending editorial review._
Connections
topiramate off-label weight is a side effect of
Sources
- Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations. (2023) pubmed
- Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery. (2021) pubmed
- Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. (2014) pubmed
- Topiramate: antipsychotic-induced weight gain. (2014) pubmed
- Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review. (2023) pubmed
- Five-year Weight Loss Maintenance With Obesity Pharmacotherapy. (2023) pubmed
- Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery. (2024) pubmed
- Use of Weight Loss Medications in Patients after Bariatric Surgery. (2021) pubmed
- Treating obesity in type 1 diabetes mellitus - review of efficacy and safety. (2024) pubmed
- Long-term drug treatment for obesity: a systematic and clinical review. (2014) pubmed